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Introduction
Human platelets express two thrombin receptors, protease-activated receptor (PAR) 1 and PAR4 [1, 2] .
Comparatively less research has been performed on PAR4, perhaps because it was shown early that PAR1 had a higher affinity for thrombin [3] [4] [5] . However, work from the Kuliopolos laboratory in 2000 demonstrated that platelet PAR1 mediates a rapid but transient platelet calcium signaling response to thrombin, whereas PAR4 mediates a slower, sustained rise, producing the majority of the calcium response [6] . PAR4 also plays a more important role in thrombin generation than PAR1 [7] . As compared with platelets from white individuals, platelets from black individuals are hyper-reactive when stimulated with the AYPGKF activation peptide (AP) that specifically stimulates PAR4 [8] [9] [10] . Genome-wide approaches identified a G/A single-nucleotide polymorphism (SNP) in the gene encoding PAR4 (F2RL3), rs773902, that accounted for ⁓ 50% of the racial variation in PAR4 activity [9] . The G/A SNP of rs773902 results in either an alanine (Ala) or threonine (Thr), respectively, at position 120 in the second transmembrane domain, with the Thr-containing variant being more common in blacks than in whites (allelic frequencies of 63% and 19%, respectively [9] ). The reasons for the differences in signaling and kinetics between PAR1 and PAR4 and between PAR4-Ala120 and PAR4-Thr120 are incompletely understood, in part because of a lack of suitable reagents and a murine model. Thus, the naturally occurring and common functional PAR4-Ala120Thr genetic variant provides a unique opportunity to gain a deeper understanding of PAR biology and PAR1-PAR4 relationships.
Although platelet activation with PAR4-AP is dependent on the rs773902 polymorphism, it is important to characterize the thrombin response, for multiple reasons. First, thrombin is the major in vivo physiological agonist for PAR4, and AYPGKF is an artificial sequence that does not occur in vivo [11] ; furthermore, PAR signaling can differ between thrombin APs and PAR-APs [12] . PAR-APs are used at micromolar or milimolar concentrations, and do not allow assessment of relevant thrombin concentrations for PAR activation. Second, because thrombin functions as a platelet agonist through both platelet PAR4 and PAR1 [13] , and because PAR4 has been shown to heterodimerize with PAR1 [13] , it is critical to characterize thrombin-induced PAR4 signaling in human platelets expressing both PAR4 and PAR1. Finally, acute coronary syndrome patients who are homozygous A for rs773902 showed less bleeding in a clinical trial of the PAR1 blocker vorapaxar [14] , but a direct effect of the PAR4 variant on platelets inhibited with vorapaxar has not been studied.
The goals of the current study were to assess the effects of the PAR4 variant on stimulation by the physiological agonist thrombin, the actions of common antiplatelet agents, and the risk of in vivo thrombotic events. We now report the PAR4-Ala120Thr variant regulates low-dose thrombin-induced platelet aggregation, and that the Thr120 isoform is relatively resistant to desensitization. In addition, we report an effect of the rs773902 genotype on the risk of stroke.
Materials and methods

Subject recruitment and genotyping
Healthy human donors aged between 21 years and 60 years of self-identified race from the greater Philadelphia area were screened and genotyped for rs773902 (Fig. S1 ) in F2RL3 with the TaqMan SNP Genotyping Assay (Life Technologies, Carlsbad, CA, USA). Because the rs773902 A allele is less common in the general population but more common in blacks than in whites, we recruited more blacks than whites (we screened 109 black donors and 75 white donors). The exclusion criteria are shown in Fig. 1 . Of the 184 screened donors, 17 blacks and 16 whites met the inclusion criteria and were available to be recalled for ex vivo platelet studies for the duration of the study.
Platelet aggregation, activation, and desensitization
Washed platelets were prepared and adjusted to 2 9 10 8 platelets mL -1 in Tyrode's buffer (137 mM NaCl, 2.7 mM KCl, 0.485 mM NaH 2 PO 4 , 12 mM NaHCO 3 , 25 mM HEPES, 1 mM MgCl 2 , 2 mM CaCl 2 , 0.1% glucose, 0.35% bovine serum albumin, pH 7.35) as previously described [8, 15] . Platelet aggregation was measured by use of a PAP-8E Aggregometer with 0.5 mg mL À1 arachidonic acid (Bio/Data Corporation, Horsham, PA, USA), a-thrombin (1 nM = 0.1 U mL
À1
; Enzyme Research Laboratories, South Bend, IN, USA), PAR1-AP (SFLLRN), and PAR4-AP (AYPGKF) (GL Biochem, Shanghai, China). ATP release from washed platelets was measured with a Chronolog Model 700 aggregometer (Chrono-Log, Havertown, PA, USA), according to the manufacturer's instructions. P-selectin expression and calcium mobilization were measured by flow cytometry as previously described [10, 16] .
Desensitization was performed as previously described [17] [18] [19] ; washed platelets were incubated with 100-300 lM PAR4-AP or 10 lM PAR1-AP in the presence of 0.5 lM prostaglandin I 2 for 30 min, and this was followed by aggregometry with PAR4-AP or PAR1-AP.
isothiocyanate antibody (Sigma-Aldrich, St Louis, MO, USA) by the use of flow cytometry.
Bioluminescence resonance energy transfer (BRET)
HEK293 cells (1 9 10 5 ) were transfected with donor plasmid HA-PAR1-Luc or HA-P2Y12-Luc and increasing amounts (0-1 lg) of acceptor plasmid (PAR4-120T-green fluorescent protein [GFP] or PAR4-120A-GFP), and stimulated with 10 nM a-thrombin for 10 min; this was followed by the addition of 5 lM luciferase substrate (Coelenterazine 400a; Biotium, Hayward, CA, USA). Both PAR4 constructs were phenylalanine at residue 296. Emission was detected with a Perkin Elmer Victor 3 plate reader equipped with the appropriate BRET2 filter set. The BRET signal was calculated as the ratio of emission at 515 nm to emission at 410 nm minus the BRET in the absence of GFP, as previously described [20] [21] [22] .
Platelet lipid raft fractionation
Platelet lipid raft fractionation was performed as described previously [23] . Untreated or stimulated (1 nM thrombin) washed platelets were lysed, fractionated on a 5-30% sucrose gradient, and centrifuged at 200 000 9 g for 18 h. Twelve equal fractions were collected, blotted on a nitrocellulose membrane, and immunoblotted for GM1 with Cholera Toxin B subunit (Sigma-Aldrich) or anti-PAR4 14H6 [24] .
Antagonist studies
Washed platelets were incubated with various concentrations of the PAR1 inhibitor vorapaxar (Axon Medchem, Reston, VA, USA), the PAR4 inhibitor BMS-986120 (Cayman Chemical, Ann Arbor, MI, USA), the P2Y 12 inhibitors ticagrelor (Selleckchem, Houston, TX, USA) or 2-methylthioadenosine 5 0 -monophosphate triethylammonium salt hydrate (MeSAMP) (Sigma Aldrich), or the cyclooxygenase inhibitor acetylsalicylic acid (ASA) (Sigma-Aldrich), and maximal aggregation or calcium mobilization was measured.
Stroke association study
Genotype and phenotype data were downloaded from the Stroke Genetics Network (SiGN) study, containing > 11 000 individuals from the National Center for Biotechnology Information (NCBI) repository via the NCBI database of Genotypes and Phenotypes [25] . The SiGN is a large international collaboration designed to detect genetic variants that predispose to subtypes of ischemic stroke. Fig. 1 . Subject recruitment and exclusion criteria. Healthy subjects were recruited and genotyped for rs773902. Written informed consent was obtained from all participants with the approval of the Institutional Review Board of Thomas Jefferson University in Philadelphia, PA. This flow diagram illustrates who was excluded from recall for the laboratory platelet studies. Failure to aggregate in response to arachidonic acid was assumed to reflect non-steroidal anti-inflammatory drug use; 'healthy' was arbitrarily defined as the use of no more than one prescription medication not known to affect platelet function; 37 were lost to follow-up after genotyping or otherwise not able to be recalled. Of the 33 eligible subjects identified during the 3-year study, at least 20 were available for recall at any given time.
scale [26] . rs773902 genotypes were extracted with PLINK v1.07 [27] . Because the control population was exclusively white (N control = 832) and the prevalence of the PAR4 variant differs by race [9] , only data from the self-identified white cases (N cases = 7338) were used, to avoid confounding with race. Among these cases, 6255 had rs773902 genotype information (Table S1 ). Each TOAST subgroup of the SiGN was analyzed for overall stroke risk. We employed multivariate logistic regression models for stroke outcome, and included both categorical and continuous variables as potential contributors to stroke risk. The rs773902 A allele was considered to be the risk allele in a dominant model (heterozygous AG or homozygous AA), a recessive model (homozygous AA) and an additive model (A allele copy number) after controlling for the stroke risk contributions of age, gender, hypertension, smoking, and diabetes status. We also examined models that included an interaction effect between diabetes and genotype for the impact on stroke risk, because of prior reports indicating a relationship between diabetes and PAR4 [28] , and our finding of an interaction between genotype and diabetes status.
Results
Platelet aggregation in response to thrombin is enhanced by the rs773902 AA genotype Healthy donors were recruited, genotyped, and recalled for ex vivo platelet studies. Prior work with 154 donors [9] and additional preliminary studies showed that heterozygotes have an intermediate phenotype for platelet functional assays, so platelet function comparisons were limited to subjects homozygous for rs773902 AA or GG, encoding Thr/Thr and Ala/Ala, respectively (Fig. 1) . As expected, there were more self-identified blacks with the rs773902 AA genotype. There were no significant differences in age, gender, body mass index or hematological parameters between the two study groups (Table 1) .
Thrombin dose-response curves demonstrated that platelet aggregation was initiated at~0.3 nM thrombin, and that platelets from subjects with the rs773902 AA genotype had a leftward-shifted dose-response curve relative to subjects with the rs773902 GG genotype (P = 0.022; Fig. 2A , B, solid lines). The concentration of thrombin required to produce 50% maximal aggregation (EC50) was significantly lower for platelets from rs773902 AA homozygotes than for platelets from rs773902 GG homozygotes (0.41 AE 0.02 nM and 0.49 AE 0.02 nM, respectively, P < 0.001). Because there were more females in the GG genotype group, additional analyses were performed and showed no gender effect on thrombin response (Fig. 2C ). In addition, the genotype effect on the thrombin doseresponse curves did not vary by race (Fig. 2D,E) . The number of platelet surface PARs did not differ by genotype (Fig. S2) . When PAR-APs were used, an even greater effect of genotype was observed (Fig. S3) , presumably because thrombin-induced activation of PAR1 shifts the agonist dose-response curve further leftward for rs773902 GG homozygous platelets, and a PAR1-mediated shift does not occur with PAR4-AP. Thus, as compared with rs773902 GG homozygous platelets, rs773902 AA homozygous platelets show enhanced platelet aggregation in response to thrombin regardless of gender or race.
PAR4-PAR1 interaction during low-concentration thrombininduced platelet aggregation
Because PAR4 has a lower affinity for thrombin than does PAR1 [3, 5, 29] , it has generally been thought that PAR4 activation requires a substantially higher thrombin concentration [4] . However, the data in Fig. 2 obtained by the use of human platelets with PAR4 variants imply an effect of PAR4 at low thrombin concentrations. Consequently, we tested the contribution of PAR1 and PAR4 to thrombin stimulation following inhibition with vorapaxar and BMS-986120, respectively. We found that 400 nM BMS-986120 fully inhibited PAR4-AP aggregation in both rs773902 A genotype (Fig. S4A ) and G genotype subjects (data not shown). Neither BMS-986120 nor vorapaxar had an effect on activation of the non-targeted receptor by peptides (Fig. S4B,C) .
Inhibition of PAR4 with the PAR4-specific BMS-986120 compound shifted the thrombin dose-response Note that the numbers of white rs773902 AA subjects are small because they represent only~4% of the population, and the numbers of black rs773902 GG subjects are small because they represent only~6% of the population. Genotype differences between thrombin dose-response curves were measured with repeated-measures ANOVA. [Color figure can be viewed at wileyonlinelib rary.com] curves of both genotypes to the right (Fig. 2B , dotted lines; P < 0.0001). In the absence of PAR4 signaling, PAR1-induced platelet aggregation began at~0.5 nM thrombin and the EC50 increased to~0.7 nM. These data indicate that PAR4 contributes to thrombin-induced platelet aggregation at low thrombin concentrations in the range of~0.4 nM to~0.8 nM (i.e. the difference between the solid and dotted lines in Fig. 2B ). There was no significant difference between the two genotype curves for the PAR1-mediated thrombin dose response. Inhibition of PAR1 with vorapaxar caused an even greater rightward shift in the thrombin dose-response curves (Fig. 2B , dashed lines; P < 0.0001). In the absence of PAR1 signaling, PAR4-induced platelet aggregation began at~0.8 nM thrombin and the average EC50 increased to~1.0 nM. Although there was no statistically significant difference between thrombin dose-response curves obtained with vorapaxar treatment, there is a suggestion that the genotype effect may persist in the 0.8-1.0 nM thrombin range. Finally the data in Fig. 2 also suggest that maximal platelet aggregation may be greater for PAR4 alone than for PAR1 alone (~72% versus 57%). Because glycoprotein (GP) Iba can also bind thrombin and activate PAR1 [30] , we considered whether GPIba was contributing to the low-dose thrombin response. SZ2, a GPIba-specific mAb that blocks thrombin binding [31, 32] , had no effect on rs773902 AA or GG aggregation at 0.45 nM thrombin (Fig. S5) , indicating that GPIba does not contribute to the low-dose thrombin response. Collectively, these data indicate that PAR4 contributes to platelet aggregation at low thrombin concentrations.
The kinetic effect of rs773902 on platelet aggregation in response to thrombin It has recently been shown that Gq and G13 activation is increased by purified PAR4-Thr120 as compared with purified PAR4-Ala120, peaking at ⁓ 2 min; thereafter, the genotype effect is lost [33] . Therefore, we determined whether there were genotype effects on time-dependent platelet aggregation. In the absence of PAR inhibitors, the genotype difference persisted for 15 min at 0.4 nM and 0.5 nM thrombin, but was lost at 0.6 nM thrombin (Fig. 3A) . Inhibition of PAR4 blocked the genotype difference at all thrombin concentrations (Fig. 3B) . When PAR1 was blocked, there was an apparent genotype effect only at low concentrations (< 1.2 nM) and at early time points (~200-400 s) (Fig. 3C) , an effect that was not observed at the fixed 15-min time point in Fig. 2B .
Genotypic differences in thrombin-induced feedback mechanisms of platelet activation
Both activation of PAR4 and activation of PAR1 induce granule release as a feedback mechanism to enhance and stabilize platelet aggregation, with PAR1 producing reversible aggregation, and PAR4 producing irreversible aggregation [6, 17, 34] . We therefore considered whether the PAR4 variant might alter granule release. As compared with platelets from rs773902 GG donors stimulated with low concentrations of thrombin, platelets from rs773902 AA donors showed a small increase in a-granule release (P = 0.044; Fig. 4A ) and more substantial dense granule release (P = 0.02 at 1 nM thrombin; Fig. 4B ).
Platelets with the F2RL3 AA genotype are resistant to desensitization
We considered a number of potential molecular mechanisms that might account for the PAR4-Ala120 Thr-dependent difference in thrombin-induced platelet aggregation. First, COS7 cells were transfected with Nterminally FLAG-tagged PAR4 expression plasmids for each variant, but no significant difference was observed in thrombin cleavage of the two isoforms (Fig. 5A) . Second, using HEK293 cells transiently expressing PAR1 and PAR4, we did not observe differences in heterodimerization between the rs773902 AA and rs773902 GG variants as measured by BRET fluorescence (Fig. 5B) . Third, because residue 120 of PAR4 faces externally in the second transmembrane region, and a Thr (polar) substitution for Ala (non-polar) may be more likely to interact with the lipid bilayer, we considered whether the variant altered localization in lipid microdomains of platelets from different donors. Lipid raft fractions were probed by immunoblots for PAR4, but neither variant was observed to localize in the raft fraction (Fig. 5C) . Finally, PAR4 has been shown to abrogate PAR1 signaling desensitization [35] , but the effect of the F2RL3 rs773902 genotype has not been considered. As shown in Fig. 5D ,E, rs773902 GG platelets were fully desensitized with 100 lM PAR4-AP, whereas rs773902 AA platelets were minimally affected (P = 0.03 and P = 0.34, respectively). As compared with rs773902 GG platelets, rs773902 AA platelets required a three-fold increased concentration of PAR4-AP for complete desensitization ( Fig. 5F ; P < 0.001). Desensitization of PAR1 or PAR4 had no significant effect on response to the other PAR receptor (Fig. S6) . Although there are limitations to the cell line assays (Fig. 5A,B) , the simplest interpretation of these data is that the rs773902 genotype difference in thrombin sensitivity may be mediated by receptor desensitization and trafficking.
Pharmacogenetic effect of the Ala120Thr variant on antiplatelet antagonists
The current management of cardiovascular disease is based largely on clinical studies that have included primarily white subjects who have a low (~20%) frequency of the rs773902 A allele [9] , and we next sought to address whether there is an ex vivo pharmacogenetic effect of rs773902 on antiplatelet drugs. Because of interindividual differences in thrombin EC50s (even within genotype), a thrombin dose-response investigation was performed on each donor's platelets. Platelets from both genotypes were subsequently incubated with varying concentrations of the PAR1 inhibitor vorapaxar, and stimulated with the concentration of thrombin required to cause 80% aggregation (EC80), which averaged 0.59 nM in the 16 donors. There was no significant difference by genotype in the vorapaxar dose response of aggregation inhibition when stimulation was performed with an EC80 amount of thrombin ( Fig. 6A ; P = 0.35). In contrast, when platelets were stimulated with a fixed dose of 1 nM thrombin, the vorapaxar IC50 was 1.8-fold higher for platelets from rs773902 AA donors than for platelets from rs773902 GG donors ( Fig. 6B ; P < 0.0001). These data are consistent with the vorapaxar effect shown in Figs 2B and 3C. As ADP is a critical second messenger released from dense granules, the greater ATP release observed in rs773902 AA platelets (Fig. 4B ) raised the possibility that these platelets may be less responsive to P2Y 12 inhibitors. Platelets from both genotypes were incubated with varying concentrations of the non-competitive P2Y 12 inhibitor ticagrelor, and stimulated with either an EC80 amount of thrombin determined for each individual subject, or with a fixed dose of 1 nM thrombin. There was no significant difference in sensitivity to ticagrelor either at an EC80 concentration of thrombin (Fig. 6C) or at 1 nM thrombin (Fig. 6D) . This indicates that P2Y 12 function is important for the rs773902 genotype effect at subnanomolar thrombin concentrations. In contrast, the IC50 of the competitive P2Y 12 antagonist (MeSAMP) for 1 nM thrombin-induced platelet aggregation was six-fold higher for platelets from rs773902 AA donors than for platelets from rs773902 GG donors (Fig. S7A ). The rs773902 genotype had no effect on the ability of cyclooxygenase inhibition by ASA to attenuate thrombininduced platelet aggregation (Fig. S7B ).
F2RL3 variant association with stroke risk
Public datasets with genome-wide genotype data and atherothrombotic outcomes were examined to determine whether individuals with the F2RL3 rs773902 A allele had an increased risk of having platelet-related ischemic clinical outcomes. The SiGN was the only large study that included both relevant clinical outcome data and rs773902 genotype data [25] . Table S1 shows the number of patients by genotype and stroke subtype, totaling 6255. Association analysis demonstrated strong positive associations with stroke risk for the correlates male gender, older age (≥ 75 years), smoking, hypertension and diabetes across the various models, so we analyzed the rs773902 A allele contribution to risk after controlling for these factors as well as an interaction for diabetes status. Table 2 shows that the rs773902 A allele was associated with an increased stroke risk (all TOAST categories) (odds ratio increase of 1.166 for each additional copy of A; (Fig. 2B) , and would be expected to be sensitive to the effects of ADP. P-values were determined with Student's t-test (B) and with an extra sum-of-squares F-test for the differences in IC50s. [Color figure can be viewed at wileyonlinelibrary.com] confidence interval [CI] 1.006-1.356, P = 0.044); in addition, large-artery stroke showed an odds ratio increase of 1.232 for each additional copy of A (CI 0.997-1.524, P = 0.053). A full listing of the regression models and results is given in Table S2 , and shows that the rs773902 A allele demonstrated a modest but consistent pattern of trending for stroke risk across the three dominant, recessive or dose-dependent genetic models.
Discussion
The clinical and functional importance of PAR4 has been less well evaluated than that of PAR1. In this study, we used a common and naturally occurring PAR4 functional variant to better define the role of PAR4 in thrombininduced platelet activation. The major findings of our investigations are as follows: (i) the F2RL3 rs773902 SNP alters in vitro platelet reactivity at subnanomolar concentrations of thrombin and at early time points, but genotype differences are overcome at higher thrombin concentrations and longer time points -this indicates that both PAR1 and PAR4 contribute to a subnanomolar thrombin response; (ii) the enhanced rs773902 AA reactivity is eliminated by P2Y 12 antagonism with ticagrelor, and, at low thrombin concentrations, by vorapaxar; and (iii) rs773902 AA platelets are more resistant to receptor desensitization. In addition, we provide evidence that the rs773902 A allele is associated with the risk of stroke in white patients. Like other functional genomic variants [36, 37] , rs773902 has the same in vitro effect regardless of self-identified race (Fig. 2D,E) . As the frequency of the rs773902 A allele is more than three times higher in blacks of Sub-Saharan East African ancestry than in whites, the allele frequency may contribute to racial disparities in the outcomes of cardiovascular disease. Most studies using heterologous cell systems have shown that one to two orders of magnitude higher thrombin concentrations are required to induce signaling through PAR4 than signaling through PAR1 [3, 4] . These, coupled with the lack of a high-affinity binding site for athrombin [4] , have supported the idea that PAR4 cleavage and activation occur only at high thrombin concentrations. Using human platelets, we found that 0.4-0.5 nM thrombin achieves 50% aggregation (EC50) of washed platelets, which is a finding similar to that reported by Leger et al. [13] . Importantly, the significantly different EC50s between the two PAR4 variants indicate a role of PAR4 in platelet aggregation at the steep part of the thrombin dose-response curve. When PAR1 is inhibited by vorapaxar, the thrombin dose-response and time-response data support a persistent genotype effect only at early time points with low concentrations of thrombin ( Figs 2B and 3C ). These thrombin-stimulated platelet aggregation data are consistent with the faster G-protein binding kinetics demonstrated with purified PAR4 variant proteins preincubated with PAR4-AP [33] . Although in vivo concentrations of thrombin in the local microenvironment of a forming thrombus are unknown, it is believed that there is a concentration gradient of agonists from the tightly packed core of the thrombus to the outer shell [38] [39] [40] [41] [42] . One can imagine that, as the thrombin concentrations decrease along this gradient, there is a region where thrombin will activate rs773902 AA platelets, but not rs773902 GG platelets, leading to differences in the size and structure of the thrombus.
The genotype effect on the agonist dose response appeared to be greater for PAR4-AP than for thrombin ( Figs 2B and S2) . The simplest explanation is that thrombin activation of PAR1 induces a leftward shift in the curve that overcomes the relative 'hyporeactivity' of rs773902 GG platelets. However, other possible explanations include different PAR4 conformations stabilized by the tethered ligand as compared with the AP, which indicates coupling to different G-proteins [12] . Differential genotype-mediated dimerization with other G-proteincoupled receptors could also result in different signaling in response to the tethered ligand or AP.
Initial mechanistic studies showed similar surface expression of PAR4, receptor cleavage, dimerization and lipid raft localization between the two F2RL3 genotypes, and no effect of GPIba, although deeper investigation into these mechanisms may be warranted. However, significant differences in PAR4 desensitization were observed. It is well established that stimulation of a PAR in the presence of an inhibitor of aggregation results in 'desensitization' of that receptor [43, 44] . Such desensitization has been used as a tool to uncouple PAR4 signaling from PAR1 signaling in response to thrombin, and has been a valuable approach for studying post-PAR cleavage signaling events [13, 35, 45, 46] . Although the exact mechanism of PAR desensitization is not fully understood, it is thought to involve a combination of post-translational modification and internalization to prevent further downstream signaling. It was recently shown that PAR4-Thr120-P2Y 12 heterodimers mediate PAR4 internalization and enhanced signaling in heterologous cell lines [47, 48] . Because secreted ADP enhances PAR-induced platelet signaling and activation [49] , we hypothesized that the Thr120 variant favors PAR4-P2Y 12 heterodimer formation. Such a mechanism would be consistent with our observed increased dense granule release in PAR4-Thr120 platelets (Fig. 4B) , as well as the inability of the ADP competitive inhibitor MesAMP to overcome the genotype effect of low-dose thrombin activation (Fig. S7) . Although coimmunoprecipitation experiments showed increased PAR4-P2Y 12 heterodimerization in PAR4-Thr120-expressing HEK293 cells, similar BRET studies did not demonstrate a genotype effect (Figs S8 and S9 ). Perhaps our experimental conditions did not support a BRET-identified PAR4 variant effect, and additional work is needed to address whether the Thr120 variant favors PAR4-P2Y 12 heterodimer formation and to more accurately define a role for ADP and P2Y 12 in the hyper-reactive PAR4-Thr120 phenotype. Nevertheless, our data obtained with a non-competitive P2Y 12 inhibitor (ticagrelor) demonstrate a functional (if not physical) interaction between PAR4 and P2Y 12 that differs by PAR4 variant.
There are many genomic studies considering associations between vascular ischemic events and platelet gene variants, but few of these were performed with a genotyping platform with good coverage of common variants in PAR4. Our analysis of the SiGN cohort showed that individuals bearing the rs773902 A allele had a pattern of greater risk for ischemic stroke. Although our study is the largest to date on the in vitro effects of thrombin on the PAR4-Ala120Thr variant, a larger sample size would enable consideration of other confounding genetic or demographic variables. However, the small but significant association between the rs773902 A allele and ischemic stroke seen in the~7000 stroke patients reported in our study (Table 2 ) and the reduction in bleeding associated with the rs773902 AA genotype seen in~7000 ischemic coronary patients receiving antiplatelet therapy [14] provide important support for the in vivo importance of this genetic variant. Together with our functional data, these clinical association signals warrant further study, including of an rs773902-diabetes interaction.
The importance of understanding the physiological effects of the common PAR4-A120T variant is underscored by the critical role of thrombin in platelet thrombus formation and the recent interest in PAR4 inhibition as a therapeutic strategy (e.g. BMS-986141 and BMS-986120) [50] [51] [52] . Our results have demonstrated that the rs773902 genotype alters ex vivo thrombin-induced platelet reactivity, affects receptor desensitization, and is associated with a modest stroke risk. These results have potential clinical significance in atherothrombotic disease, in which the PAR4 variant could modify ischemic or hemorrhagic outcomes despite currently used antiplatelet agents. It will be important for future antiplatelet clinical trials to test for pharmacogenetic interactions with the PAR4 variant and to develop antiplatelet therapies with good efficacy against platelets expressing the rs773902 A allele (predominantly black patients). PAR4 blockade may be beneficial in this regard if the novel compounds are not sensitive to rs773902 genotype effects in the presence of low-dose thrombin-induced platelet reactivity. Alternatively, combination antiplatelet therapy that includes a non-competitive, allosteric antagonist of P2Y 12 may be beneficial.
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